Literature DB >> 34312451

Corneal inflammatory cell infiltration predicts disease activity in chronic inflammatory demyelinating polyneuropathy.

Jeremias Motte1,2, Thomas Grüter3,4, Dietrich Sturm4,5,6, Kalliopi Pitarokoili3,4, Anna Lena Fisse3,4, Yesim Bulut3,4, Zornitsa Stykova3,4, Tineke Greiner5, Elena Enax-Krumova4,5, Min-Suk Yoon4,7, Ralf Gold3,4, Martin Tegenthoff4,5.   

Abstract

The assessment of disease activity is fundamental in the management of chronic inflammatory demyelinating polyneuropathy (CIDP). Previous studies with small patient numbers found an increase of corneal immune cell infiltrates as a potential marker of inflammation in patients with CIDP. However, its clinical relevance remained unclear. The present study aimed to determine whether the amount of corneal inflammatory cells (CIC) measured by corneal confocal microscopy (CCM) detects disease activity in CIDP. CIC were measured in 142 CCM-investigations of 97 CIDP-patients. Data on clinical disease activity, disability (INCAT-ODSS) and need for therapy escalation at the timepoint of CCM, 3 and 6 months later were analyzed depending CIC-count. Pathological spontaneous activity during electromyography was examined as another possible biomarker for disease activity in comparison to CIC-count. An increased CIC-count at baseline was found in patients with clinical disease activity and disability progression in the following 3-6 months. An increase to more than 25 CIC/mm2 had a sensitivity of 0.73 and a specificity of 0.71 to detect clinical disease activity and a sensitivity of 0.77 and a specificity of 0.64 to detect disability progression (increasing INCAT-ODSS) in the following 6 months. An increase to more than 50 CIC/mm2 had a sensitivity of about 0.51 and a specificity of 0.91 to detect clinical disease activity and a sensitivity of 0.53 and a specificity of 0.80 to detect disability progression. CIC count is a non-invasive biomarker for the detection of disease activity in the following 6 months in CIDP.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34312451     DOI: 10.1038/s41598-021-94605-7

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  25 in total

Review 1.  Advances in the diagnosis, pathogenesis and treatment of CIDP.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

Review 2.  Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment.

Authors:  Helmar Christoph Lehmann; David Burke; Satoshi Kuwabara
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-04-16       Impact factor: 10.154

3.  Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment.

Authors:  Gisa Ellrichmann; Ralf Gold; Ilya Ayzenberg; Min-Suk Yoon; Christiane Schneider-Gold
Journal:  Ther Adv Neurol Disord       Date:  2016-12-09       Impact factor: 6.570

4.  CIDP diagnostic pitfalls and perception of treatment benefit.

Authors:  Jeffrey A Allen; Richard A Lewis
Journal:  Neurology       Date:  2015-07-15       Impact factor: 9.910

5.  Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Min-Suk Yoon; Andrew Chan; Ralf Gold
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

6.  Disease activity in chronic inflammatory demyelinating polyneuropathy.

Authors:  Hana Albulaihe; Majed Alabdali; Abdulla Alsulaiman; Alon Abraham; Ari Breiner; Carolina Barnett; Hans D Katzberg; Leif E Lovblom; Bruce A Perkins; Vera Bril
Journal:  J Neurol Sci       Date:  2016-08-16       Impact factor: 3.181

Review 7.  Ultrasound and MRI of nerves for monitoring disease activity and treatment effects in chronic dysimmune neuropathies - Current concepts and future directions.

Authors:  Bernhard F Décard; Mirko Pham; Alexander Grimm
Journal:  Clin Neurophysiol       Date:  2017-11-10       Impact factor: 3.708

8.  Pathological spontaneous activity as a prognostic marker in chronic inflammatory demyelinating polyneuropathy.

Authors:  T Grüter; J Motte; A L Fisse; Y Bulut; N Köse; D Athanasopoulos; S Otto; M-S Yoon; C Schneider-Gold; R Gold; K Pitarokoili
Journal:  Eur J Neurol       Date:  2020-09-09       Impact factor: 6.089

Review 9.  Comprehensive approaches for diagnosis, monitoring and treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  Anna Lena Fisse; Jeremias Motte; Thomas Grüter; Melissa Sgodzai; Kalliopi Pitarokoili; Ralf Gold
Journal:  Neurol Res Pract       Date:  2020-12-08

Review 10.  In Vivo Confocal Microscopy of the Human Cornea in the Assessment of Peripheral Neuropathy and Systemic Diseases.

Authors:  Ellen F Wang; Stuti L Misra; Dipika V Patel
Journal:  Biomed Res Int       Date:  2015-12-07       Impact factor: 3.411

View more
  1 in total

1.  Corneal Confocal Microscopy and the Nervous System: Introduction to the Special Issue.

Authors:  Rayaz A Malik; Nathan Efron
Journal:  J Clin Med       Date:  2022-03-08       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.